	US 11,780,904 B2
	Method of producing recombinant high molecular weight vWF in cell culture
Leopold Grillberger, Vienna (AT); Manfred Reiter, Vienna (AT); and Wolfgang Mundt, Vienna (AT)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Oct. 30, 2020, as Appl. No. 17/86,072.
Application 17/086,072 is a division of application No. 16/125,141, filed on Sep. 7, 2018, granted, now 10,822,394.
Application 15/201,125 is a division of application No. 14/339,319, filed on Jul. 23, 2014, granted, now 9,409,971, issued on Aug. 9, 2016.
Application 14/339,319 is a division of application No. 13/179,386, filed on Jul. 8, 2011, granted, now 8,852,888, issued on Oct. 7, 2014.
Application 16/125,141 is a continuation of application No. 15/591,022, filed on May 9, 2017, granted, now 10,100,099, issued on Oct. 16, 2018.
Application 15/591,022 is a continuation of application No. 15/201,125, filed on Jul. 1, 2016, granted, now 9,834,591, issued on Dec. 5, 2017.
Claims priority of provisional application 61/362,635, filed on Jul. 8, 2010.
Prior Publication US 2021/0115110 A1, Apr. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/755 (2006.01); C12N 9/64 (2006.01); A61K 9/00 (2006.01); A61K 38/36 (2006.01); A61K 38/37 (2006.01); C12P 21/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/755 (2013.01) [A61K 9/0019 (2013.01); A61K 38/36 (2013.01); A61K 38/37 (2013.01); C12N 9/6489 (2013.01); C12P 21/00 (2013.01); A61K 38/00 (2013.01); C12N 2500/24 (2013.01); C12N 2511/00 (2013.01); C12Y 304/24087 (2013.01)]

20 Claims

1. A composition comprising isolated soluble recombinant Von Willebrand Factor (rVWF), wherein the composition has an NH₄⁺ concentration of below 4 mM or below 10 mM, wherein the composition contains at least 0.5 IU ristocetin cofactor activity per mL, and wherein at least 20% of the isolated soluble rVWF in the composition is present in a high molecular weight VWF multimer of more than 10 dimers.